Introduction: Advances in the treatment of erectile dysfunction

European Urology, Supplement

Volumn 1, Issue 8, 2002, Pages 1-3

  Giuliano, François ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Apomorphine; Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

APOMORPHINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

COMORBIDITY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INTERNET; PATIENT EDUCATION; PENIS ERECTION; PREVALENCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUALITY;

EID: 0036870144     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00111-2     Document Type: Conference Paper

References (15)

1. Padma-Nathan H, Giuliano F. Oral drug therapy for erectile dysfunction. Urol Clin North Am 2001;28:321-34.
2. Jardin A, Wagner G, Khoury S, Giuliano F, Goldstein I, Padma-Nathan H, editors. Recommendations of the First International Consultation on Erectile Dysfunction, cosponsored by the World Health Organization (WHO). Plymouth: Health Publications Ltd, 2000, p. 709-26.
3. Aytaç IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6.
4. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000;12:305-11.
5. Burchardt M, Burchardt T, Anastasiadis AG. Kiss AJ, Shabsigh A, De La Taille A, Pawar RV, Baer L, Shabsigh R. Erectile dysfunction is a marker for cardiovascular complications and psychological functioning in men with hypertension. Int J Impot Res 2001;13: 276-81.
6. Buvat J, Lemaire A, Buvat-Herbaut M, Guieu JD, Bailleul JP, Fossati P. Comparative investigations in 26 impotent and 26 nonimpotent diabetic patients. J Urol 1985;133:34-8.
7. O'Kane PD, Jackson G. Erectile dysfunction: is there silent obstructive coronary artery disease? Int J Clin Pract 2001;55:219-20.
8. Kirby M, Jackson G, Betteridge J, Friedl K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 2001;55: 614-8.
9. Lewis RW, Hatzichristou DG, Laumann E, McKinlay JB. Epidemiology and natural history of erectile dysfunction: risk factors including iatrogenic and ageing. In: Jardin A, Wagner G, Khoury S, Giullano F, Goldstein I, Padma-Nathan H, editors. Recommendations of the First International Consultation on Erectile Dysfunction, cosponsored by the World Health Organization (WHO). Plymouth: Health Publication Ltd; 2000. p. 21-51.
10. Giuliano F, Chevret-Measson M, Tsatsaris A, Reitz C, Murino M, Thonneau P. Prevalence of erectile dysfunction in France: Results of an epidemiological survey of a representative sample of 1004 men. Eur Urol 2002;42:382-9.
11. Meuleman EJ, Donkers LH, Robertson C, Keech M, Boyle P, Kiemeney LA. Erectile dysfunction: prevalence and effect on the quality of life Boxmeer study. Ned Tijdschr Geneeskd 2001;145:576-81.
12. Chew KK, Earle CM, Stuckey BGA, Jamrozik K, Keogh EJ. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res 2000;12:41-5.
13. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999;162:722-5.
14. Casabé A, Cobreros C, Bechara A, Roletto L, Chéliz G, Hochman S. Drop out reason in responders to sildenafil. Int J Impot Res 2001;13(Suppl 2):S5 [moderated poster 9].
15. Hatzichristou DG. Sildenafil failures may be due to inadequate instructions and follow-up: a study on 100 non-responders. Int J Impot Res 2001:13:S32 [abstract 85].